ArticleScientific reports2025
Integrating transcriptomic and epigenomic data to identify potential biomarkers in gestational diabetes mellitus patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Delineating novel diagnostic biomarkers and therapeutic targets for oral submucosal fibrosis: an integrative multi-omics and machine learning approach.Frontiers in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gestational diabetes mellitus (GDM), one of the prevalent pregnancy-related metabolic disorders, have shown immediate or long-term adverse health outcomes for maternal and fetal health. Therefore, it is crucial to understand the ongoing cellular and molecular changes in GDM patients for characterizing novel biomarkers for diagnosis and therapeutic purposes. In the current study, we analyzed 3 transcriptomic datasets, characterized 449 unique upregulated and 785 downregulated DEGs, and performed several analyses. Gene ontology shows enrichment of migration, development, and immune-related processes in GDM patients. KEGG pathway shows enrichment of pathways like "type 1 diabetes mellitus" and "graft versus host disease". Disease ontology shows enrichment of "female reproductive system disease," "anemia," etc. Integration of methylation and transcriptomic data identified 11 genes (RASSF2, WSCD1, TNFAIP3, TPST1, UBASH3B, ZFP36, CRISPLD2, IGFBP7, TNS3, TPM2, and VTRNA1-2), as potential novel diagnostic biomarkers and therapeutic targets. Furthermore, immune cell-type infiltration analysis shows higher memory B-cells and lower M1 macrophages and CD8 T-cells. Protein-protein interaction analysis followed by ROC analysis in an independent dataset identified 7 hub genes (POLR2G, VWF, COL5A1, COL6A1, CD44, COL3A1, and COL1A1) with high diagnostic potential. Overall, we obtained 18 genes that could serve as novel diagnostic biomarkers and therapeutic targets in GDM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.